Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GRK6 | P43250 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312199 | 0.91 | FLT3 (0.45) | FLT3GSK3AGSK3BGRK6PIK3CA | |
| SCHEMBL10312118 | 0.91 | FLT3 (0.46) | FLT3MAPTGSK3AGSK3BKDR | |
| SCHEMBL10312123 | 0.89 | MELK (0.45) | FLT3SMN1; SMN2GRK6MEN1KMT2A | |
| SCHEMBL16556851 | 0.87 | IGF1R (0.46) | FLT3MAPTGSK3AGSK3BKDR | |
| SCHEMBL16556839 | 0.85 | GRK6 (0.33) | FLT3MAPTGRK6EGFRPIK3CA | |
| SCHEMBL10312171 | 0.83 | HRH4 (0.46) | MAPTPIK3CAMTORKMT2ALMNA | |
| SCHEMBL10312201 | 0.81 | FLT3 (0.46) | FLT3GSK3AGSK3BKDRGRK6 | |
| SCHEMBL16556935 | 0.81 | KDM4E (0.34) | FLT3GSK3AGSK3BKDRSMN1; SMN2 | |
| SCHEMBL10312150 | 0.79 | IGF1R (0.48) | FLT3 | |
| SCHEMBL10312176 | 0.79 | MELK (0.46) | FLT3GSK3AGSK3BKDRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440055-B1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY LLC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | FLT3 152/4885MAPT 1313/4885GSK3A 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.